George Padron Contributing Editor Only Healthcare Today

George Padron

Contributing EditorOnly Healthcare Today

George Padron is a distinguished contributing editor for Only Healthcare Today. With a background rooted in the ancient art of philosophical inquiry and a keen eye for the evolving landscape of modern medicine, George brings a unique perspective to his analyses.

Born and raised amidst the historic libraries of a quaint Iberian town, George's early fascination with the human condition led him to pursue extensive studies in the humanities, culminating in a doctorate from a venerable European institution. His academic career saw him lecturing on the intricate connections between societal well-being and technological advancement, often drawing parallels between classical thought and contemporary challenges.

As a contributing editor, George specializes in the ethical implications of emerging healthcare technologies, the socio-economic impact of global health policies, and the philosophical underpinnings of patient-centered care. His articles are renowned for their intellectual depth, insightful commentary, and ability to bridge complex academic concepts with accessible, real-world applications. When not immersed in research or writing, George can often be found exploring ancient ruins or tending to his collection of rare botanical specimens.


Mapping Parkinson's Genetics Beyond European Ancestry

Mapping Parkinson's Genetics Beyond European Ancestry

George Padron
Precision Medicine, Biomarker & Genomic Testing, Neurology & Mental Health, Movement Disorders | Aug 5, 2026
A Lancet Neurology study of nearly 100,000 people found Parkinson's causal and risk variants differ sharply by ancestry, with implications for trial eligibility.
Putting a Price on Exercise After Colon Cancer Treatment

Putting a Price on Exercise After Colon Cancer Treatment

George Padron
Oncology Care, GI Cancers, Managed Care, Value Based Care | Aug 4, 2026
A JCO cost-utility analysis of the CHALLENGE trial found a structured exercise program after colon cancer chemotherapy was both less costly and more effective.
AI for Managed Care Administration: Enhancement or Replacement? (Part 2)Play Video

AI for Managed Care Administration: Enhancement or Replacement? (Part 2)

George Padron
Podcasts, Healthcare Systems & Business, Digital Health & AI, Prior Authorization, Value Based Care | Aug 3, 2026
Dr. Randy Vogenberg discusses integrating AI into managed care, focusing on clinical pathways and expert guidelines. (Part 2)
A Bispecific Moved Earlier in Myeloma, and Brought Its Infection Risk With It

A Bispecific Moved Earlier in Myeloma, and Brought Its Infection Risk With It

George Padron
Oncology Care, Hematologic Malignancies, Access & Affordability, Prior Authorization | Aug 2, 2026
MajesTEC-9 in NEJM found teclistamab monotherapy improved progression-free and overall survival in earlier-line myeloma, with common grade 3-4 infections.
A Blood Test's Blind Spots: Discrepancies Between P-tau217 and Clinical Alzheimer's Disease

A Blood Test's Blind Spots: Discrepancies Between P-tau217 and Clinical Alzheimer's Disease

George Padron
Precision Medicine, Biomarker & Genomic Testing, Neurology & Mental Health, Alzheimer's & Dementia | Aug 1, 2026
P-tau217 was identified as the strongest blood marker for clinical Alzheimer's disease in a study of 1,817 Caribbean Hispanic adults; however, 37% of diagnosed patients tested negative.
Barrett's Surveillance Shifts to a Risk-Based Footing

Barrett's Surveillance Shifts to a Risk-Based Footing

George Padron
Oncology Care, Biomarker & Genomic Testing, GI Cancers, Population Health Management | Jul 30, 2026
AGA's new Barrett's esophagus guideline replaces uniform surveillance with risk-based intervals and names high-quality endoscopy as the key to cancer prevention.
Vessel Pattern, Not Just Stenosis, Predicted Angina Relief From Stenting

Vessel Pattern, Not Just Stenosis, Predicted Angina Relief From Stenting

George Padron
Specialty Medicine, Cardiology, Managed Care, Value Based Care | Jul 28, 2026
An ORBITA-2 analysis in JACC found focal coronary disease predicted far greater placebo-controlled angina relief from PCI than diffuse disease.
AI for Managed Care Administration: Enhancement or Replacement? (Part 1)Play Video

AI for Managed Care Administration: Enhancement or Replacement? (Part 1)

George Padron
Podcasts, Healthcare Systems & Business, Digital Health & AI, Prior Authorization, Value Based Care | Jul 27, 2026
Dr. Randy Vogenberg discusses integrating AI into managed care, focusing on clinical pathways and expert guidelines.
In Standard-Risk Myeloma, Two Years of Maintenance Equals Indefinite Therapy

In Standard-Risk Myeloma, Two Years of Maintenance Equals Indefinite Therapy

George Padron
Oncology Care, Hematologic Malignancies, Access & Affordability, Drug Pricing & Out-of-Pocket, Managed Care, Value Based Care | Jul 23, 2026
In standard-risk myeloma without an up-front transplant, stopping lenalidomide maintenance at 2 years matched indefinite therapy on survival, with fewer harms.
Hospital at Home and Heart Failure Care Equally Effective, But Clinician Judgment Most Important

Hospital at Home and Heart Failure Care Equally Effective, But Clinician Judgment Most Important

George Padron
Specialty Medicine, Cardiology, Managed Care, Value Based Care | Jul 21, 2026
Kaiser's hospital-at-home program matched inpatient care on 30-day readmission, mortality, and GDMT in 307 matched heart failure pairs. Cost was not assessed.
Load More
Only Healthcare Today Covering Clinical Healthcare, Access and Cost

Only Healthcare Today
Covering Clinical Healthcare, Access and Cost

1 Hewitt Square, Suite 139
East Northport, NY 11731

Who We Are


About Us Editorial Policy Contributors & Partners

Connect


Contact Us Work With Us Advertising Terms of Use Privacy Policy